Erasca Inc

NASDAQ:ERASUnited States

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.

Contact Information

Headquarters

10835 Road To The Cure, Suite 140SAN DIEGO, CA, United States 92121-1130

Phone

858-465-6511

Fax

302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder

Jonathan Lim

Chief Financial Officer and Chief Business Officer

David Chacko

Chair of Research and Development

Michael Varney

General Counsel, Corporate Secretary

Ebun Garner

Chief Medical Officer

Shannon Morris